

## THIS HANDBOOK IS NOT INTENDED TO BE A SUBSTITUTE FOR MEDICAL ADVICE

Please refer to the **Patient Information Leaflet** in the pack for full safety information and instructions for injection.

### REPORTING OF SIDE EFFECTS

▼ Dupixent (dupilumab) is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you get any side effects, talk to your healthcare professional. This includes any possible side effects not listed in this booklet or the package leaflet.

You can also tell us about side effects directly via the national reporting systems below:

#### In the UK:

Through the national MHRA Yellow Card scheme reporting system:  
[www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)

#### In Ireland:

Website: [www.hpra.ie](http://www.hpra.ie)  
Email: [medsafety@hpra.ie](mailto:medsafety@hpra.ie)  
Tel: +353 1 6764971

#### Alternatively contact Sanofi Genzyme on:

+44 (0)800 0902314 (UK)  
+353 1 403 5600 (Ireland)

By reporting side effects, you can help provide more information on the safety of this medicine.

**DUPIXENT**<sup>®</sup>   
(dupilumab)

## DUPIXENT DOSING CALENDAR

**THIS PATIENT CALENDAR IS FOR ADULTS AND  
ADOLESCENTS 12 YEARS AND OLDER WITH  
MODERATE-TO-SEVERE ATOPIC DERMATITIS  
WHO HAVE BEEN PRESCRIBED DUPIXENT.**

Please refer to the Patient Information Leaflet for full safety information and instructions for injection.

Although every effort is made to ensure the accuracy of the information in this handbook, you should consult your healthcare professional for specific advice about your condition. Sanofi Genzyme cannot accept any liability for any reliance you place on general advice in this handbook.

**SANOFI GENZYME** 

Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.

SAGB.DUP.17.10.1332b(2)  
SAIE.DUP.20.01.0017(1)  
February 2020

**SANOFI GENZYME** 

Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.

# WELCOME TO YOUR DUPIXENT DOSING CALENDAR!

You have been prescribed Dupixent (dupilumab) for your atopic dermatitis (AD).

Dupixent blocks proteins in your body that play a major role in the development of AD, to help give you control of your condition.

Your healthcare professional will tell you how much Dupixent you need, for how long and with which device. You may use Dupixent on its own or with other eczema medicines that you apply to the skin, although you may find you need to rely less on these in the future.

It is important to follow the treatment plan that you and your healthcare professional have agreed upon. This calendar is a simple way to help you manage your own treatment and keep track of your injections, appointments and milestones.

➤ **It is important to remember to take your dose of Dupixent every two weeks in order for it to be effective.**

If you have forgotten to inject a dose of Dupixent, please talk to your healthcare professional. Do not stop using Dupixent without speaking to your healthcare professional first.

➤ **Programming injection reminders in your smart phone is a good way to stay on track.**

➤ **Remember to remove the Dupixent pre-filled syringe or pen from the fridge 45 minutes before injecting, but you must not leave it out of the fridge for longer than 14 days.**

Do not return the Dupixent pre-filled syringe or pen to the fridge. If you need to permanently remove the carton from the fridge, write down the date of removal in the space provided on the outer carton, and use Dupixent within 14 days. Always ensure that the pre-filled syringes or pen are stored in their original carton to protect the medicine from light.

You can also use the space provided in the following pages to take notes during your treatment. It may be helpful to keep a record of your progress and any questions you may have about your treatment. You can discuss these notes with your healthcare professional at your next visit.

















